Article Text

Download PDFPDF
Daratumumab as a rescue therapy in severe refractory anti-SRP immune-mediated necrotising myopathy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Handling editor Josef S Smolen

  • Contributors OL-C, HA-C, HC, SD, ER and JB-T contributed to the acquisition, analysis or interpretation of data, drafted the work or revised it critically for important intellectual content and approved the final version to be published.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests OL-C reports participation to advisory boards from Abbvie, Astra-Zeneca, Janssen and Roche. HAC reports honoraria as speaker from Abbvie, Janssen, Pfizer, Mantra Pharma, Eli Lilly, Amgen, Sobi, AstraZeneca, Sandoz and Novartis; participation to advisory boards from Novartis, Amgen, Hoffmann-La Roche, Eli Lilly, Abbvie, BMS and Novartis; and participation in clinical studies sponsored by Pfizer, Neomed, Daiichi Sankyo Inc, Abbvie, Xencor, Sanofi and Novartis. HA-C, SD, ER report no disclosure. JB-T reports honoraria as speaker from GSK, Teva, Amgen and Pfizer; and participation to advisory boards from Astra-Zeneca, Abbvie, Janssen, Novartis, Teva and Pfizer.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.